JP Morgan Chase
NNNN

JP Morgan Chase’s Anbio Biotechnology NNNN Stock Holding History

JP Morgan Chase’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$718 Buy
+53
New +$1.33K ﹤0.01% 7372

Other funds holding NNNN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BFS
Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.81B AUM 32.31% 1-Year Est. Return

JP Morgan Chase's NNNN Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Anbio Biotechnology (NNNN) in Q2 2026: 53 shares worth $718. The stake represents ﹤0.01% of the portfolio and ranks #7372 among its holdings.

12 funds tracked by Wall St. Rank hold NNNN as of Q2 2026.

  • JP Morgan Chase held 53 shares of Anbio Biotechnology worth $718 as of Q2 2026.
  • Anbio Biotechnology was a new JP Morgan Chase position in Q2 2026.
  • Anbio Biotechnology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7372 holding.
  • 12 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.